Little Apple Pediatrics , a Chinese children’s clinic chain founded in 2014, has closed a Pre-D strategic round and isn’t saying how much it raised. The deal surfaced on November 14, 2026, in a funding announcement from Little Apple Pediatrics that Sina Finance ran on Sohu.
No amount, then. What you can measure is the business the money goes into: 10 clinics in China’s first-tier cities, handling nearly 100,000 patient visits a year.


The backers include an unnamed “well-known AI company” and CEC Health Fund (中电健康基金), plus other investors the announcement doesn’t list. The company says the named investors will work with it on AI pediatric services, but it gave no stake sizes, no valuation and no start date for that work.
Most of the cash goes to one build, an AI digital service system inside the clinics. It covers growth assessment, psychological screening, posture screening, follow-up management and digital health records, and all five sit inside the 10 existing clinics. Child endocrinology, which handles growth and hormone problems, is the chain’s lead specialty. There’s no date yet for when patients will see any of it.
“This round will go mainly into building the AI digital service system in our clinics and improving how well we turn AI medical technology into practical use.”
Lu Bo, founder of Little Apple Pediatrics
Lu Bo came out of the drug business. By 2013 he was a Johnson & Johnson executive with 13 years in pharmaceutical sales behind him, and he left to start the chain, according to a 2015 founder profile on cn-healthcare.
This isn’t the chain’s first outside money. It earlier closed a RMB 50 million Series B led by CITIC Capital’s healthcare fund, and said at the time it would spend on pediatric specialists, doctor training and more clinics. The new announcement mentions no earlier rounds and no total raised.
What does a round with no amount tell you?
Less than you’d want: you get the chain’s size and nothing about the money. Split nearly 100,000 visits evenly across 10 clinics and each one handles under 10,000 visits a year (100,000 ÷ 10 = 10,000), or fewer than 28 a day over 365 days (10,000 ÷ 365 ≈ 27.4).
What’s missing is what an investor would price on: round size, valuation, revenue and the AI company’s name. Without the first two, you can’t tell whether the Pre-D round is bigger or smaller than the RMB 50 million Series B. Whether AI spending pays back is the question Nebuly raised a $21 million Series A to measure for corporate AI buyers, and Little Apple Pediatrics has published no measure of its own.
Two things to watch: whether the AI investor gets named, and whether a business-registration change in China shows the new shareholders and their stakes.